Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.
Adjuvant treatment of postmenopausal women w/ hormone receptor +ve early invasive breast cancer. Advanced breast cancer in postmenopausal women w/ hormone receptor +ve or hormone receptor unknown locally advanced or metastatic breast cancer.
Adult & elderly 1 mg once daily.
Early disease Recommended treatment duration: 5 yr.
May be taken with or without food.
Hypersensitivity. Premenopausal women. Co-administration w/ oestrogen-containing therapies. Concurrent tamoxifen therapy. Severe renal impairment (CrCl <20 mL/min). Moderate or severe hepatic disease. Pregnancy & lactation.
L02BG03 - anastrozole ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.